Global RNAi for Therapeutic Market Research Report 2025

RNAi for Therapeutic Market

RNA interference (RNAi) therapeutics is an advanced molecular medicine technology that utilizes double-stranded RNA molecules (such as siRNA or shRNA) to selectively silence target gene expression, thereby blocking pathogenic gene transcription or translation to achieve precise treatment of various genetic disorders, rare diseases, cancers, and viral infections. Without altering the DNA sequence, RNAi therapy offers reversible, highly specific, and low-toxicity interventions at the RNA level. Since the approval of the first RNAi drug, the field has rapidly transitioned from research to commercialization, showing immense potential in targeting the liver, nervous system, and oncology. With breakthroughs in delivery systems and expanding clinical pipelines, RNAi therapeutics is emerging as a strategic pillar in precision medicine and gene therapy industries.

The global deployment of RNAi therapeutics is accelerating, driven by multiple dimensions: breakthroughs in genomics and RNA biology have enabled higher-precision drug design; advancements in novel delivery technologies such as lipid nanoparticles (LNP) and GalNAc conjugates have significantly improved targeting efficiency to the liver and other tissues; and fast-track review policies by regulatory agencies in multiple countries have shortened the path from R&D to commercialization. Leading pharmaceutical and biotech companies are actively expanding the range of clinical indications through mergers, acquisitions, and collaborations, facilitating the market rollout of RNAi therapies in rare diseases, metabolic disorders, and cardiovascular diseases.Despite its disruptive potential, RNAi therapeutics faces technical, commercial, and regulatory hurdles. Delivery efficiency and tissue specificity remain key bottlenecks, especially in achieving effective delivery to the central nervous system and solid tumors. Additionally, RNAi molecules may trigger non-specific immune responses or off-target effects, affecting both safety and efficacy. From a business perspective, high production costs and stringent quality control standards constrain scalability and profit margins. Intellectual property barriers and the concentration of core patents among a few leading companies further raise the technical and legal thresholds for new entrants.Demand in downstream markets is becoming increasingly segmented and diversified. Rare disease treatment, lacking effective therapies, is highly reliant on RNAi solutions, making it an early commercialization breakthrough. Cardiovascular and metabolic diseases, with their vast patient populations, offer long-term growth potential. In oncology and immunotherapy, RNAi is forming novel combination approaches with checkpoint inhibitors, CAR-T, and other treatments. With the rise of personalized medicine and companion diagnostics, RNAi therapies will become more deeply integrated into precision stratification and targeted intervention clinical pathways, driving demand toward higher efficiency, safety, and controllability.

This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.

The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global RNAi for Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the RNAi for Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of RNAi for Therapeutic Market Report

Chapter Outline

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global RNAi for Therapeutic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 siRNA

1.2.3 miRNA

1.2.4 shRNA

1.3 Market by Application

1.3.1 Global RNAi for Therapeutic Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Cancer

1.3.3 Cardiovascular

1.3.4 HBV

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2.1 Global RNAi for Therapeutic Market Perspective (2020-2031)

2.2 Global RNAi for Therapeutic Growth Trends by Region

2.2.1 Global RNAi for Therapeutic Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 RNAi for Therapeutic Historic Market Size by Region (2020-2025)

2.2.3 RNAi for Therapeutic Forecasted Market Size by Region (2026-2031)

2.3 RNAi for Therapeutic Market Dynamics

2.3.1 RNAi for Therapeutic Industry Trends

2.3.2 RNAi for Therapeutic Market Drivers

2.3.3 RNAi for Therapeutic Market Challenges

2.3.4 RNAi for Therapeutic Market Restraints

3.1 Global Top RNAi for Therapeutic Players by Revenue

3.1.1 Global Top RNAi for Therapeutic Players by Revenue (2020-2025)

3.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2020-2025)

3.2 Global Top RNAi for Therapeutic Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by RNAi for Therapeutic Revenue

3.4 Global RNAi for Therapeutic Market Concentration Ratio

3.4.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2024

3.5 Global Key Players of RNAi for Therapeutic Head office and Area Served

3.6 Global Key Players of RNAi for Therapeutic, Product and Application

3.7 Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global RNAi for Therapeutic Historic Market Size by Type (2020-2025)

4.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031)

5.1 Global RNAi for Therapeutic Historic Market Size by Application (2020-2025)

5.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031)

6.1 North America RNAi for Therapeutic Market Size (2020-2031)

6.2 North America RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America RNAi for Therapeutic Market Size by Country (2020-2025)

6.4 North America RNAi for Therapeutic Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7.1 Europe RNAi for Therapeutic Market Size (2020-2031)

7.2 Europe RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe RNAi for Therapeutic Market Size by Country (2020-2025)

7.4 Europe RNAi for Therapeutic Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8.1 Asia-Pacific RNAi for Therapeutic Market Size (2020-2031)

8.2 Asia-Pacific RNAi for Therapeutic Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region (2020-2025)

8.4 Asia-Pacific RNAi for Therapeutic Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9.1 Latin America RNAi for Therapeutic Market Size (2020-2031)

9.2 Latin America RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America RNAi for Therapeutic Market Size by Country (2020-2025)

9.4 Latin America RNAi for Therapeutic Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa RNAi for Therapeutic Market Size (2020-2031)

10.2 Middle East & Africa RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country (2020-2025)

10.4 Middle East & Africa RNAi for Therapeutic Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11.1 Alnylam Pharmaceuticals

11.1.1 Alnylam Pharmaceuticals Company Details

11.1.2 Alnylam Pharmaceuticals Business Overview

11.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction

11.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)

11.1.5 Alnylam Pharmaceuticals Recent Development

11.2 Arrowhead Pharmaceuticals

11.2.1 Arrowhead Pharmaceuticals Company Details

11.2.2 Arrowhead Pharmaceuticals Business Overview

11.2.3 Arrowhead Pharmaceuticals RNAi for Therapeutic Introduction

11.2.4 Arrowhead Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)

11.2.5 Arrowhead Pharmaceuticals Recent Development

11.3 Arrowhead

11.3.1 Arrowhead Company Details

11.3.2 Arrowhead Business Overview

11.3.3 Arrowhead RNAi for Therapeutic Introduction

11.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025)

11.3.5 Arrowhead Recent Development

11.4 Silence Therapeutics

11.4.1 Silence Therapeutics Company Details

11.4.2 Silence Therapeutics Business Overview

11.4.3 Silence Therapeutics RNAi for Therapeutic Introduction

11.4.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)

11.4.5 Silence Therapeutics Recent Development

11.5 Benitec Biopharma

11.5.1 Benitec Biopharma Company Details

11.5.2 Benitec Biopharma Business Overview

11.5.3 Benitec Biopharma RNAi for Therapeutic Introduction

11.5.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025)

11.5.5 Benitec Biopharma Recent Development

11.6 Phio Pharmaceuticals

11.6.1 Phio Pharmaceuticals Company Details

11.6.2 Phio Pharmaceuticals Business Overview

11.6.3 Phio Pharmaceuticals RNAi for Therapeutic Introduction

11.6.4 Phio Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)

11.6.5 Phio Pharmaceuticals Recent Development

11.7 RXi Pharmaceuticals

11.7.1 RXi Pharmaceuticals Company Details

11.7.2 RXi Pharmaceuticals Business Overview

11.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction

11.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)

11.7.5 RXi Pharmaceuticals Recent Development

11.8 Arrakis Therapeutics

11.8.1 Arrakis Therapeutics Company Details

11.8.2 Arrakis Therapeutics Business Overview

11.8.3 Arrakis Therapeutics RNAi for Therapeutic Introduction

11.8.4 Arrakis Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)

11.8.5 Arrakis Therapeutics Recent Development

11.9 Benitec Biopharma

11.9.1 Benitec Biopharma Company Details

11.9.2 Benitec Biopharma Business Overview

11.9.3 Benitec Biopharma RNAi for Therapeutic Introduction

11.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025)

11.9.5 Benitec Biopharma Recent Development

11.10 miRagen Therapeutics

11.10.1 miRagen Therapeutics Company Details

11.10.2 miRagen Therapeutics Business Overview

11.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction

11.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)

11.10.5 miRagen Therapeutics Recent Development

11.11 Sylentis

11.11.1 Sylentis Company Details

11.11.2 Sylentis Business Overview

11.11.3 Sylentis RNAi for Therapeutic Introduction

11.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2020-2025)

11.11.5 Sylentis Recent Development

11.12 Gradalis

11.12.1 Gradalis Company Details

11.12.2 Gradalis Business Overview

11.12.3 Gradalis RNAi for Therapeutic Introduction

11.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2020-2025)

11.12.5 Gradalis Recent Development

11.13 Sirnaomics

11.13.1 Sirnaomics Company Details

11.13.2 Sirnaomics Business Overview

11.13.3 Sirnaomics RNAi for Therapeutic Introduction

11.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025)

11.13.5 Sirnaomics Recent Development

11.14 Silenseed

11.14.1 Silenseed Company Details

11.14.2 Silenseed Business Overview

11.14.3 Silenseed RNAi for Therapeutic Introduction

11.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2020-2025)

11.14.5 Silenseed Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

 Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

 Table 2. Key Players of siRNA

 Table 3. Key Players of miRNA

 Table 4. Key Players of shRNA

 Table 5. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

 Table 6. Global RNAi for Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

 Table 7. Global RNAi for Therapeutic Market Size by Region (2020-2025) & (US$ Million)

 Table 8. Global RNAi for Therapeutic Market Share by Region (2020-2025)

 Table 9. Global RNAi for Therapeutic Forecasted Market Size by Region (2026-2031) & (US$ Million)

 Table 10. Global RNAi for Therapeutic Market Share by Region (2026-2031)

 Table 11. RNAi for Therapeutic Market Trends

 Table 12. RNAi for Therapeutic Market Drivers

 Table 13. RNAi for Therapeutic Market Challenges

 Table 14. RNAi for Therapeutic Market Restraints

 Table 15. Global RNAi for Therapeutic Revenue by Players (2020-2025) & (US$ Million)

 Table 16. Global RNAi for Therapeutic Market Share by Players (2020-2025)

 Table 17. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)

 Table 18. Ranking of Global Top RNAi for Therapeutic Companies by Revenue (US$ Million) in 2024

 Table 19. Global 5 Largest Players Market Share by RNAi for Therapeutic Revenue (CR5 and HHI) & (2020-2025)

 Table 20. Global Key Players of RNAi for Therapeutic, Headquarters and Area Served

 Table 21. Global Key Players of RNAi for Therapeutic, Product and Application

 Table 22. Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry

 Table 23. Mergers & Acquisitions, Expansion Plans

 Table 24. Global RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)

 Table 25. Global RNAi for Therapeutic Revenue Market Share by Type (2020-2025)

 Table 26. Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)

 Table 27. Global RNAi for Therapeutic Revenue Market Share by Type (2026-2031)

 Table 28. Global RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)

 Table 29. Global RNAi for Therapeutic Revenue Market Share by Application (2020-2025)

 Table 30. Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)

 Table 31. Global RNAi for Therapeutic Revenue Market Share by Application (2026-2031)

 Table 32. North America RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

 Table 33. North America RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)

 Table 34. North America RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)

 Table 35. Europe RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

 Table 36. Europe RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)

 Table 37. Europe RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)

 Table 38. Asia-Pacific RNAi for Therapeutic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

 Table 39. Asia-Pacific RNAi for Therapeutic Market Size by Region (2020-2025) & (US$ Million)

 Table 40. Asia-Pacific RNAi for Therapeutic Market Size by Region (2026-2031) & (US$ Million)

 Table 41. Latin America RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

 Table 42. Latin America RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)

 Table 43. Latin America RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)

 Table 44. Middle East & Africa RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

 Table 45. Middle East & Africa RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)

 Table 46. Middle East & Africa RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)

 Table 47. Alnylam Pharmaceuticals Company Details

 Table 48. Alnylam Pharmaceuticals Business Overview

 Table 49. Alnylam Pharmaceuticals RNAi for Therapeutic Product

 Table 50. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 51. Alnylam Pharmaceuticals Recent Development

 Table 52. Arrowhead Pharmaceuticals Company Details

 Table 53. Arrowhead Pharmaceuticals Business Overview

 Table 54. Arrowhead Pharmaceuticals RNAi for Therapeutic Product

 Table 55. Arrowhead Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 56. Arrowhead Pharmaceuticals Recent Development

 Table 57. Arrowhead Company Details

 Table 58. Arrowhead Business Overview

 Table 59. Arrowhead RNAi for Therapeutic Product

 Table 60. Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 61. Arrowhead Recent Development

 Table 62. Silence Therapeutics Company Details

 Table 63. Silence Therapeutics Business Overview

 Table 64. Silence Therapeutics RNAi for Therapeutic Product

 Table 65. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 66. Silence Therapeutics Recent Development

 Table 67. Benitec Biopharma Company Details

 Table 68. Benitec Biopharma Business Overview

 Table 69. Benitec Biopharma RNAi for Therapeutic Product

 Table 70. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 71. Benitec Biopharma Recent Development

 Table 72. Phio Pharmaceuticals Company Details

 Table 73. Phio Pharmaceuticals Business Overview

 Table 74. Phio Pharmaceuticals RNAi for Therapeutic Product

 Table 75. Phio Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 76. Phio Pharmaceuticals Recent Development

 Table 77. RXi Pharmaceuticals Company Details

 Table 78. RXi Pharmaceuticals Business Overview

 Table 79. RXi Pharmaceuticals RNAi for Therapeutic Product

 Table 80. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 81. RXi Pharmaceuticals Recent Development

 Table 82. Arrakis Therapeutics Company Details

 Table 83. Arrakis Therapeutics Business Overview

 Table 84. Arrakis Therapeutics RNAi for Therapeutic Product

 Table 85. Arrakis Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 86. Arrakis Therapeutics Recent Development

 Table 87. Benitec Biopharma Company Details

 Table 88. Benitec Biopharma Business Overview

 Table 89. Benitec Biopharma RNAi for Therapeutic Product

 Table 90. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 91. Benitec Biopharma Recent Development

 Table 92. miRagen Therapeutics Company Details

 Table 93. miRagen Therapeutics Business Overview

 Table 94. miRagen Therapeutics RNAi for Therapeutic Product

 Table 95. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 96. miRagen Therapeutics Recent Development

 Table 97. Sylentis Company Details

 Table 98. Sylentis Business Overview

 Table 99. Sylentis RNAi for Therapeutic Product

 Table 100. Sylentis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 101. Sylentis Recent Development

 Table 102. Gradalis Company Details

 Table 103. Gradalis Business Overview

 Table 104. Gradalis RNAi for Therapeutic Product

 Table 105. Gradalis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 106. Gradalis Recent Development

 Table 107. Sirnaomics Company Details

 Table 108. Sirnaomics Business Overview

 Table 109. Sirnaomics RNAi for Therapeutic Product

 Table 110. Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 111. Sirnaomics Recent Development

 Table 112. Silenseed Company Details

 Table 113. Silenseed Business Overview

 Table 114. Silenseed RNAi for Therapeutic Product

 Table 115. Silenseed Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

 Table 116. Silenseed Recent Development

 Table 117. Research Programs/Design for This Report

 Table 118. Key Data Information from Secondary Sources

 Table 119. Key Data Information from Primary Sources

 Table 120. Authors List of This Report

List of Figures

 Figure 1. RNAi for Therapeutic Picture

 Figure 2. Global RNAi for Therapeutic Market Size Comparison by Type (2020-2031) & (US$ Million)

 Figure 3. Global RNAi for Therapeutic Market Share by Type: 2024 VS 2031

 Figure 4. siRNA Features

 Figure 5. miRNA Features

 Figure 6. shRNA Features

 Figure 7. Global RNAi for Therapeutic Market Size by Application (2020-2031) & (US$ Million)

 Figure 8. Global RNAi for Therapeutic Market Share by Application: 2024 VS 2031

 Figure 9. Cancer Case Studies

 Figure 10. Cardiovascular Case Studies

 Figure 11. HBV Case Studies

 Figure 12. Others Case Studies

 Figure 13. RNAi for Therapeutic Report Years Considered

 Figure 14. Global RNAi for Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031

 Figure 15. Global RNAi for Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031

 Figure 16. Global RNAi for Therapeutic Market Share by Region: 2024 VS 2031

 Figure 17. Global RNAi for Therapeutic Market Share by Players in 2024

 Figure 18. Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

 Figure 19. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2024

 Figure 20. North America RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 21. North America RNAi for Therapeutic Market Share by Country (2020-2031)

 Figure 22. United States RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 23. Canada RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 24. Europe RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 25. Europe RNAi for Therapeutic Market Share by Country (2020-2031)

 Figure 26. Germany RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 27. France RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 28. U.K. RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 29. Italy RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 30. Russia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 31. Ireland RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 32. Asia-Pacific RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 33. Asia-Pacific RNAi for Therapeutic Market Share by Region (2020-2031)

 Figure 34. China RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 35. Japan RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 36. South Korea RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 37. Southeast Asia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 38. India RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 39. Australia & New Zealand RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 40. Latin America RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 41. Latin America RNAi for Therapeutic Market Share by Country (2020-2031)

 Figure 42. Mexico RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 43. Brazil RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 44. Middle East & Africa RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 45. Middle East & Africa RNAi for Therapeutic Market Share by Country (2020-2031)

 Figure 46. Israel RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 47. Saudi Arabia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 48. UAE RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

 Figure 49. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 50. Arrowhead Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 51. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 52. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 53. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 54. Phio Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 55. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 56. Arrakis Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 57. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 58. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 59. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 60. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 61. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 62. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

 Figure 63. Bottom-up and Top-down Approaches for This Report

 Figure 64. Data Triangulation

 Figure 65. Key Executives Interviewed